2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

2:30PM-4:00PM: Abstract Number: 1821

Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain

4M096: Spondyloarthritis Including Psoriatic Arthritis – Clinical III: Miscellaneous (1818–1823)

2:30PM-4:00PM: Abstract Number: 1798

Time to Bridge the Gap in Rheumatology Education: Interactive Team Based Learning Is Most Effective in Increasing Internal Medicine Residents’ Knowledge

4M089: Education (1794–1799)

2:30PM-4:00PM: Abstract Number: 1838

Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial

4M098: Vasculitis – Non-ANCA-Associated & Related Disorders II: Large Vessel Vasculitis Treatment (1836–1841)

2:30PM-4:00PM: Abstract Number: 1837

Ustekinumab for the Treatment of Giant Cell Arteritis

4M098: Vasculitis – Non-ANCA-Associated & Related Disorders II: Large Vessel Vasculitis Treatment (1836–1841)

2:30PM-4:00PM: Abstract Number: 1802

Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics

4M090: Infection-Related Rheumatic Disease (1800–1805)

2:30PM-4:00PM: Abstract Number: 1799

Wellness and Resiliency Among Recent Rheumatology Fellowship Graduates: A Qualitative Study

4M089: Education (1794–1799)

4:30PM-6:00PM: Abstract Number: 1885

A Search to the Target Tissue in Which RA-specific Inflammation Starts: A Detailed MRI Study to Improve Identification of RA-specific Features in the Phase of Clinically Suspect Arthralgia

4M116: RA – Diagnosis, Manifestations, & Outcomes III: Diagnosis & Prognosis (1884–1889)

4:30PM-6:00PM: Abstract Number: 1907

Abatacept Reduces Serum CXCL13 and Disease-Relevant Immune Cell Phenotypes in a Double-Blind, Placebo-Controlled Primary Sjögren’s Syndrome Clinical Trial

4M119: Sjögrenʼs Syndrome – Basic & Clinical Science (1902–1907)

4:30PM-6:00PM: Abstract Number: 1882

Anti-CCP Antibody and Pain Sensitization in Rheumatoid Arthritis

4M115: Pain Mechanisms – Basic & Clinical Science (1878–1883)

4:30PM-6:00PM: Abstract Number: 1887

Anti-Mitochondrial Antibodies Predict Severe Erosive Disease in Rheumatoid Arthritis

4M116: RA – Diagnosis, Manifestations, & Outcomes III: Diagnosis & Prognosis (1884–1889)

4:30PM-6:00PM: Abstract Number: 1886

Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors

4M116: RA – Diagnosis, Manifestations, & Outcomes III: Diagnosis & Prognosis (1884–1889)

4:30PM-6:00PM: Abstract Number: 1900

Assessing Commercial Titers of anti-Ro60 and Ro52 Antibodies to Risk Stratify Surveillance of Anti-Ro/SSA Antibody Positive Pregnancies

4M118: Reproductive Issues in Rheumatic Disorders (1896–1901)

4:30PM-6:00PM: Abstract Number: 1924

Assessing Psychosocial Needs in Juvenile Dermatomyositis Patients Across the United Kingdom

4M125: Pediatric Rheumatology: Outcomes & Quality of Life (1920–1925)

4:30PM-6:00PM: Abstract Number: 1892

Association Between Rheumatoid Arthritis Treatment and the Risk of Death or Readmission After Major Surgery

4M117: RA – Treatments III: Cardiovascular Disease & Readmissions (1890–1895)

4:30PM-6:00PM: Abstract Number: 1881

Association of Pain Centralization with DMARD Response in Active RA

4M115: Pain Mechanisms – Basic & Clinical Science (1878–1883)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].